Glycans are chains of carbohydrates attached to proteins (glycoproteins and proteoglycans) or lipids (glycolipids). Glycosylation is a post-translational modification and glycans have a wide range of functions in the human body including involvement in oncological diseases. Change in a glycan structure can not only indicate the presence of a pathological process but, more importantly, in some cases also its stage. Thus, a glycan analysis has the potential to be an effective and reliable tool in cancer diagnostics. Lectins are proteins responsible for natural biorecognition of glycans; even carbohydrate moieties still attached to proteins or whole cells can be recognised by lectins, which makes them an ideal candidate for designing label-free biosensors for glycan analysis. This review seeks to summarise evidence that the glycoprofiling of biomarkers by lectin-based biosensors can be of significant help in detecting prostate cancer.
Glycomics
Glycomics can be defined as a field of science which studies glycome. Analogically to the term "proteome" which is a set of all the proteins expressed by a cell, a tissue or an organism, or the term "genome" known as the entire genetic information of the cell, the tissue or the organism, a glycome is a set of all the glycans that are present in the cell, the tissue or the organism at a particular time (Varki & Chrispeels, 1999; Cummings & Pierce, 2014; Dalziel et al., 2014) . Glycans are defined as compounds consisting of a large number of monosaccharides linked via glycosidic bonds (André et al., 2014; Solis et al., 2014) ; however the term "glycan" is often used to describe a saccharide component of glycoproteins, glycolipids or peptidoglycans regardless of their length. As with nucleic acids or peptides, glycans also are a diverse group of molecules consisting of various numbers and types of monomer building blocks. However, unlike nucleic acids or peptides, glycans provide a much greater number of combinations and variations as monosaccharide chains can be not only linear but also branched, can be bound either by α-or β-linkages or can be linked to a polypeptide chain via oxygen (O-linked) or nitrogen atoms (Nlinked) (Cummings & Pierce, 2014; Hushegyi & Tkac, 2014; Kluková et al., 2014; Svarovsky & Joshi, 2014; Tkac et al., 2014) .
Glycosylation is an in vivo process, glycans cannot be cloned and glycosylation reactions are catalysed by enzymes known as glycosyltransferases (GTFs) (Katrlík et al., 2010; Rillahan et al., 2012; Kim et al., 2013; Wang et al., 2013a) . GTFs are a wide group of enzymes that catalyse the transfer of sugar moieties from a high-energy donor substrate to acceptor molecules (Laurent et al., 2008; Hart & Copeland, 2010; Gray et al., 2013) . To date, approximately 250 GTFs have been detected in the human genome and it is believed that genes encoding glycan biosynthesis, degradation or transport proteins form approximately 2 % of all genes (Schachter & Freeze, 2009; Freeze & Ng, 2012) . By the atom that links glycan to the protein structure, two types of glycans can be distinguished according to the linkage between polypeptide and car-*Corresponding author, e-mail: Jan.Tkac@savba.sk bohydrate chains: if the glycan is linked via oxygen, it is referred to as O-glycans and if it is linked via nitrogen as N-glycans. There are certain differences between O-glycosylation and N-glycosylation (Mariño et al., 2010) .
O-Glycans can be linked to -OH group of all amino acids, but Ser and Thr are the most common (Fig. 1) . Various monosaccharides were reported to be linked to Ser and Thr residues, e.g. Nacetylgalactosamine (Gal-NAc), N-acetylglucosamine (Glc-NAc), xylose (Xyl), mannose (Man) or fucose (Fuc) (Mariño et al., 2010) . Studies have revealed that human O-glycans contribute to many (patho)biological processes such as inflammation, coagulation, virus infections or cancer (Purcell et al., 2008) . N-glycosylation is a covalent bond between glycan and the amide group of asparagine formed during N-glycan synthesis (Fig. 2) .
The glycosylation site contains the target signal Asn-X-Ser/Thr sequence, where X can be any amino acid except for proline. N-glycosylation in an eukary- otic cell is initiated by the addition of a precursor molecule (Glc 3 Man 9 GlcNAc 2 ) to Asn of the target Fig. 2 . Synthesis of N-glycans. In the initial stage a glycan precursor, Glc 3 Man 9 ClcNAc 2 , is formed attached to the membrane and then transferred to the protein backbone. In the next step, two Glc and one Man units are trimmed and the glycan attached to the protein backbone is then further processed in the Golgi apparatus. If the glycan has a correct composition, it is secreted away from the Golgi apparatus for proper functioning inside the cell. When the glycan has an incorrect composition, it is transferred to lysosome to be recycled. Adapted from .
polypeptide chain (so-called "core protein"), which is then transferred and modified in endoplasmic reticulum (ER). This precursor plays a part in generating the three basic types of N-glycans: high-mannose, hybrid and complex. Enzymes glycosidases, present in ER, cleave three mannoses from glycosylated protein, which is then transferred to the Golgi apparatus, where the chains are prolonged by the addition of another monosaccharide (sialic acid -SA, GlcNAc, GalNAc and Fuc) by a particular GTF. The modifications in the Golgi apparatus are thus responsible for generating complex and hybrid types of N-glycans. The resulting structure is based on a combination of glycosidase (cleavage of terminal monosaccharides) and GTF (addition of terminal monosaccharides) enzymes ( Fig. 2 ) (Varki & Chrispeels, 1999; Mariño et al., 2010; .
Glycosylation
Glycosylation is the most common post-translation modification of proteins. It is estimated that approximately 50-80 % of all human proteins are glycosylated (Sparbier et al., 2005; Arnaud et al., 2013; Baker et al., 2013; Bertók et al., 2013a) . Glycans have various functions in cell signalisation, cell growth, differentiation and apoptosis, inflammation processes, immune response, etc. (Haltiwanger & Lowe, 2004; Anthony et al., 2008; Burton et al., 2012; Arthur et al., 2014; Dalziel et al., 2014; Geissner et al., 2014; Lepenies & Seeberger, 2014; Song et al., 2013; Svarovsky & Joshi, 2014 ) and a single glycoprotein can have more glycan structures Alley et al., 2013) . Differences are also found in glycan structures of the same glycoprotein expressed in various tissues since glycosylation is often cell-type specific and thus detection of an aberrant glycan structure in cancer cells compared to non-cancer cells can lead to the discovery of new cancer biomarkers (Kim & Misek, 2011; Tousi et al., 2011; Mechref et al., 2012; Hirabayashi et al., 2013; Novotny & Alley, 2013; Svarovsky & Joshi, 2014 ). An aberrant glycosylation pattern is a fundamental characteristic of tumorigenesis (Rudd & Dwek, 1997; Gilgunn et al., 2013) .
Glycans as cancer biomarkers
As cancer is the leading cause of death worldwide and new forms of treatment are still being developed, there is a growing need for the early and reliable diagnosis of this disease. Among the most widespread causes of cancer deaths worldwide are cancers of breast, prostate, lungs and ovaries (Ferlay & Soerjomataram, 2013) . As there are many cancer biomarkers that lack sensitivity or specificity, research is focused now on the role of glycans and changed glycosylation in tumorigenesis and to study changes in glycan structures in glycoprotein biomarkers. From analysis of the serum N-glycome in breast cancer patients, it has been noted that an increased sialylation, an increased levels of sLex (sialyl Lewis x) antigen and changes in fucosylation are present. Also, differences between breast cancer and benign breast disease were detected, as increased levels of agalactosyl biantennary glycans and glycans containing the sLex epitope were confirmed in breast cancer samples (Abd Hamid et al., 2008) .
The gold standard for prostate cancer detection is PSA (a prostate specific antigen) analysis in serum, but this test is becoming inadequate due to lack of specificity. By the analysis of PSA glycans, it was revealed that an increase in the amount of core fucosylation and α-(2→3)-linked SA is present in PCa (prostate cancer) samples. Triantennary trigalactosylated glycans and tetraantennary tetrasialylated glycans with outer arm Fuc were less abundant, while tetraantennary tetrasialylated glycans were more abundant in patients with advanced stages of PCa compared to patients with initial stages of PCa (Peracaula et al., 2008; Sarrats et al., 2010; . Hence, a different glycan structure not only can indicate the disease but also provide information on various disease stages.
By analysis of N-glycome from lung cancer sera, an increased level of sLex, monoantennary glycans was detected and a decreased amount of biantennary core fucosylated glycans. Also, changes in sialylation were detected when an increased level of trisialylated glycans and a decreased amount of disialylated glycans in lung cancer sera was noted (Arnold et al., 2011) . The biomarkers in use for the diagnosis of ovarian cancer are not reliable when the disease is in its early stages. Glycan analysis of the whole serum revealed an increased sLex expression and an increased core-fucosylation of agalactosylated biantennary glycans. IgG (immunoglobulin G) isolated from serum exhibited a decreased galactosylation and sialylation in ovarian cancer samples compared to the healthy control (Saldova et al., 2007) .
Prostate and prostate cancer
Two types of secretory glands are known in animal bodies, defined as exocrine and endocrine. In endocrine glands, the product is secreted directly to the blood stream unlike in exocrine glands where the product is secreted via a duct. In mammalian male reproductive systems, the prostate is a walnut-sized endocrine gland enclosing the urethra and sited between the urinary bladder and the urogenital diaphragm (Faiz & Moffat, 2002) . Its mass in the human body ranges from 7 g to 16 g, being on average approximately 11 g in an adult male (Leissner & Tisell, 1979) . The prostate gland has two main functions. First, it surrounds the urethra and its muscles can affect the urine flow and second, it has a secretory function where it secretes an acidic fluid containing serine proteases (e.g. PSA) and other semen-liquefying factors (Owen & Katz, 2005; Revenig et al., 2014) . The volume of the ejaculate contains 65-75 % of a seminal vesicles fluid, 25-30 % of prostate fluid, 5-10 % of a vasal fluid and less than 1 % of a bulbourethral glands fluid (Revenig et al., 2014) .
Benign prostate hyperplasia (BPH)
BPH is a non-neoplastic prostate disorder associated with abnormal prostate enlargement which then applies pressure on the urethra. BPH itself does not increase the probability of prostate cancer but these two conditions may occur at the same time. It is also associated with lower urinary tract symptoms (LUTC) such as increased urinary frequency and urgency, nocturia, difficulties with initiating urination, feeling of insufficient bladder emptying, weak and/or interrupted urine stream (Miller & Tarter, 2009) . BPH occurs mostly in men after 50 years of age, but it does not occur in men whose testicles were surgically removed before puberty, indicating that age and hormones are important factors in developing the disorder (Berry et al., 1984; Wang et al., 2014) .
Testosterone is a principal androgen in blood, while dihydrotestosterone is the most abundant androgen in the prostate gland (Vis & Schröder, 2009 ). The development of both malignant and benign prostate diseases is androgen-dependent; however, testosterone as the most abundant androgen is not primarily responsible for the development, growth and pathogenesis of the prostate (Lepor, 2004) . Dihydrotestosterone, a testosterone derivative, is the most potent androgenic hormone in many human organs and tissues and is a decisive androgen in the pathogenesis and progression of various diseases, e.g. BPH, prostate cancer, male pattern baldness and acne .
The examination for BPH includes prostate palpation per rectum -digital rectal examination, blood test (PSA level test), urine test (monitoring of inflammation processes in bladder), trans-rectal ultrasound to evaluate the volume of the prostate, non-invasive measurement of urine flow -uroflowmetry and the patient's evaluation of the severity of LUTC. Treatment depends on the severity of BPH, when the early stages are monitored and treatment is only initiated with the later stages of the disease. Surgical removal of the prostate is regarded as the final option.
Prostate cancer
Prostate cancer (PCa) is a disease mainly found in older men and is the most commonly diagnosed type of cancer and the third leading cause (after lung cancer and large bowel cancer) for all cancer-related deaths amongst males in the European Union (EU-27) (Ferlay et al., 2013) . PCa is a malignant disease and is frequently asymptomatic or its symptoms are similar to BPH and are therefore underestimated (Miller et al., 2003) . Benign tumour cells do not have cancer cell characteristics; do not spread to other parts of the body and the cells stay together as a single mass. Benign tumours are formed by an increased proliferation of normal tissue cells, usually are not life-threatening and their surgical removal results in a complete cure.
On the other hand, the cancer cells are altered, their proliferation is uncontrolled and their regulatory mechanisms are dysfunctional. Malign tumours can infiltrate and disrupt other tissues and body parts. If cancer cells enter the blood stream or lymphatic system, they can migrate from a primary tumour to other locations and they form secondary tumours. This is known as metastasising and secondary tumours are known as metastases (Russell, 2006 As stated above, male androgenic hormones play key roles in the origin and progression of PCa (Grossmann et al., 2013) . There are also other factors that may influence the development of PCa: age, race, lifestyle, genetic predisposition and, obviously, sex. PCa mostly affects older men: the median age at diagnosis is 67 years (Siegel et al., 2012a) . Recent studies have also revealed that patients of African ancestry are more susceptible to developing the disease than those of European or Asian ancestry. However, patients of Asian ancestry, who normally show a lower incidence of PCa, after relocating to United States had a similar incidence of the disease to that of the domestic population (Martin et al., 2013) . This is due to the environmental factors and lifestyle being different from those in Asia. Studies also show that any previous occurrence of prostate disease among family members significantly increases the risk of development of PCa (Kral et al., 2011) .
Because PCa in its earlier stages is often asymptomatic, it is very difficult to diagnose before it reaches the more advanced stages. PCa which is enclosed within the prostate gland cannot be detected using a digital rectal examination, as the gland is not enlarged. In the advanced stages, when the cancer tissue presses on the urethra and causes symptoms such as back pain and those similar to BPH, digital rectal examination is one of the two main diagnostic procedures. To confirm the PCa diagnosis, a trans-rectal ultrasound-guided biopsy needs to be carried out. The discovery of PSA (Ablin et al., 1969) was an important milestone in the analysis of PCa; however it took more than two decades before the PSA serum level test was developed (Catalona et al., 1991) and a further number of years before it became a gold standard in PCa diagnostics, as it was only approved in 1994 (Ueda et al., 2013) . However, even if the PSA test shows abnormal levels, it is not necessarily proof of PCa as elevated levels of PSA can occur not only as a result of PCa but also as a result of BPH or prostatitis (Végvári et al., 2012) . Accordingly, a biopsy is recommended as the only reliable way to confirm PCa. After the biopsy, the examined prostate tissue is evaluated using the Gleason grading system, which was developed in 1967 by Mellinger et al. (1967) and is based on awarding marks from 1 to 5 according to the microscopic appearance and tissue architecture. The Gleason score (GS) is the most frequently used method to estimate the destructive potential and prognosis of the disease. GS1 is given to a prostate tissue formed by single, separate, uniform round glands (Fig. 3A) . It resembles a normal prostate tissue as it is very welldifferentiated. When the glands are still well-formed, but have more tissue between them (i.e. the amount of stroma has increased) a GS2 is given (Fig. 3B ). Most glands are separated by less than one average gland diameter and the shape of the glands is more variable. The glands in Fig. 3C are single, separated, dark and their shape starts to be random. The glands may be closely packed but usually they are irregularly separated, with poorly defined edges. This tissue is formed by relatively uniform glands infiltrating between the benign glands. The glands may be separated by > 1 gland diameter and some of the cells begin to invade the surrounding tissue. This corresponds to a moderately differentiated carcinoma and GS3. In Fig. 3D , representing GS4, the majority of glands appear to be dispersed in the surrounding tissue and few recognisable glands are still present. The glands are chopped up and fused, with irregular edges. The glands are without stroma or small fragments of the glands are present. The nuclei are small, hyperchromatic and many cells are invading the surrounding tissue in neoplastic clusters. This corresponds to a poorly differentiated carcinoma. Fig. 3E shows carcinomas with a minimal glandular differentiation, ranging from infiltrating single cells to solid sheets of tumour cells. The tissue does not have any or has only a few recognisable glands. Cells with distinct nuclei appear in sheets within the surrounding tissue. This corresponds to an anaplastic carcinoma. The presence of GS5 and a high percentage carcinoma at prostatectomy predicts an early death (Vollmer & Humphrey, 2001; Epstein et al., 2005; Tabesh et al., 2007; WebPathology, 2014) .
Since there might be more than only one pattern present in the tissue sample, the Gleason grading system has been modified by the International Society of Urological Pathology. With this method, the pattern is given a score from 1 to 5 and then the next most common pattern is graded. Then these two scores are added to get the Gleason score. The lowest score (slowest-growing carcinoma) would be 2 and the high- est score (fastest-growing and dangerous) would be 10 (Epstein et al., 2005) . The decision to initiate the treatment is now based on the Gleason score, where a score of 2-3 in an elderly patient would only require a simple observation, because surgery or radical treatment would not be necessary. As shown in Table 1 , the new grading method also reflects the survivability of patients with PCa (Albertsen et al., 1998) . The treatment options for PCa include watchful waiting (surveillance of a medical condition without any medical intervention), radical prostatectomy, radical external beam radiation and hormone treatment (Daubenmier et al., 2006) .
Prostate cancer biomarkers
A biomarker is a biological molecule found in the blood, other bodily fluids or tissues that is a sign of a normal or abnormal process, or of a condition or a disease. A biomarker may be used to see how well the body responds to treatment for a disease or a condition. It is also known as a molecular marker or a signature molecule (National Cancer Institute, 2014) . Biomarkers are a highly heterogeneous group of molecules as they can be proteins, metabolites, nucleic acids, gene transcripts, etc. There are a few main outcomes which biomarkers should provide (Sawyers, 2008) : 1) risk assessment -what is the chance of developing the disease; 2) screening -if early detection affects survivability; 3) prognosis -prediction of outcome in the absence of a therapy; 4) diagnosis -investigation of presence of the disease and its stage; 5) prediction -selecting the most appropriate therapy and 6) monitoring -success rate of the treatment.
Moreover, an ideal biomarker should have the following aspects in order to be able to predict or diagnose a specific disease or condition (Pepe et al., 2001 ): 1) simple and safe assays; 2) provide guidance to ease decision-making; 3) establish correlation between an assessment result and a clinical condition (Fletcher et al., 2012) in a sensitive (a positive outcome when the disease is present) and a specific (a negative outcome when the disease is absent) way.
As with every other type of cancer, in PCa early diagnosis greatly improves the survivability rate (Albertsen et al., 1998) so searching for an ideal PCa biomarker is a way to decrease the mortality and also to decrease the rate of overtreatment and overdiagnosis. There is a wide range of different PCa biomarkers (Madu & Lu, 2010; Prensner et al., 2012; Fujita et al., 2014) including circulating tumour cells, gene transcripts (a prostate cancer antigen 3), gene fusions (TMPRSS2-ERG), enzymes (α-methylacyl-coenzyme A racemase (AMACR), a prostate specific antigen (PSA), prostatic acid phosphatase (PAP), metabolites (sarcosine), hormones, membrane proteins (caveolin, a prostate-specific membrane antigen (PSMA)), cell surface proteins (a prostate stem cell antigen (PSCA)), exosomes, cytokines, single-nucleotide polymorphisms (SNPs) associated with prostate cancer, an early prostate cancer antigen, haptoglobin (Hp), serum Ca 2+ , etc. However, in the subsequent text, only glycoprotein biomarkers are discussed with a description of glycan changes as a result of PCa (Table 2).
Prostatic acid phosphatase (PAP)
PAP is a glycoprotein secreted into seminal plasma by a male prostate gland epithelial tissue. It is a nonspecific phosphomonoesterase and its level increases proportionally with PCa progression (Kong & Byun, 2013) . The enzyme (EC 3.1.3.2) is a dimer of a molecular mass of 100 kDa, consisting of two sub-units of 50 kDa each (Ostrowski & Kuciel, 1994) . PAP was the first ever biomarker used for PCa diagnostics and had already been used for more than 50 years since its discovery in 1938 when it was observed that its level increased in the serum of men with a metastatic prostate (Gutman & Gutman, 1938) . There are two isoforms of PAP: one can be found in the seminal fluid (secretory PAP, sPAP) and the second can be found in an intracellular space (cellular PAP, cPAP) (Muniyan et al., 2013) . The physicochemical properties of sPAP and cPAP can vary with differences in an isoelectric point, antigenicity and glycosylation (White et al., 2009 ). The main function of PAP is to liquefy the seminal fluid (Boron & Boulpaep, 2009) ; however it has been reported that PAP also has an analgetic effect (Zylka et al., 2008) and the PAP gene can act as a PCa tumour-suppressor gene (Muniyan et al., 2014) . A normal level of cPAP in an adult male is approximately 0.5 mg g −1 of a prostatic tissue and approximately 1 mg mL −1 in the seminal fluid. As stated above, these values increase in the event of PCa presence and a massive expression occurs at a late stage of PCa with high GS (Gunia et al., 2009 ). Even though the PAP level test was replaced by the PSA level test; nowadays PAP is proposed as a valuable PCa prediction marker (Taira et al., 2007) .
Prostate specific antigen (PSA)
PSA is a 33 kDa glycoprotein enzyme produced by the epithelial cells of a prostate gland tissue. PSA belongs to a kallikrein-like peptidase family, having a chymotrypsin-like protease activity (Wu et al., 2001) , capable of catalysing the digestion of high-molecular mass proteins into bioactive peptides known as kinins (Balk et al., 2003) . PSA cleaves the semenogelin protein in order to liquefy semen coagulum, thereby allowing spermatozoa to move freely (Yoshida et al., 2009) . PSA is translated as an inactive proenzyme (proPSA) and an active PSA is produced following the cleavage of seven N-terminal amino acids. This active PSA is immediately bound by protease inhibitor, α1-antichymotrypsin, creating complexed PSA (cPSA), but a small amount of PSA circulates as free PSA (fPSA) (Zhu et al., 2013) . Further, the ratio of the fPSA level to the total PSA level can improve the specificity of PCa diagnosis (Mikolajczyk et al., 1997) .
The PSA serum level test has become a gold standard in PCa diagnosis. The normal concentration of PSA in a blood serum is below 4 ng mL −1 . A concentration higher than 10 ng mL −1 is regarded as a high risk of PCa as elevated levels of PSA are not a result of its increased expression but rather of its leakage from a damaged prostate tissue (Gilgunn et al., 2013) . However, the width of a grey zone of 4-10 ng mL −1 indicates the need for a biopsy to avoid unnecessary overdiagnoses and overtreatments (Gilgunn et al., 2013) . Nevertheless, even though PSA testing dramatically improved the PCa detection rate, there are also major drawbacks. The first is the sensitivity of the method, as the width of the grey zone does not afford a clear answer as to whether the prostate cancer is present and at what stage, and the second is the specificity, since elevated PSA levels can also be caused by pro- statitis or BPH (Bo et al., 2003) . However, due to widespread PSA testing, the possibility of discovering PCa increased while the possibility of dying is slightly decreased (Fig. 4) . Therefore, PCa screening became controversial and was subsequently ceased, because not all PCa cases may require immediate treatment. For some men, watchful waiting or active surveillance are options. Many men die with PCa rather than from it (Edwards et al., 2005) . The study of glycan structures on the surface of PSA glycoprotein could be the solution to the specificity problems. By detecting changes in glycosylation, it would be possible not only to detect PCa but also to evaluate its stage. As aberrant glycosylation is one of the characteristics of tumorigenesis, the glycan structures present on the surface of PSA from a healthy donor and from a PCa patient were compared. Different research teams (Peracaula et al., 2003; Tabarés et al., 2006; Tajiri et al., 2008; Sarrats et al., 2010) concluded that there were indeed different glycan structures when PSA from a healthy (from seminal fluid) is compared with a PCa sample. The differences were mostly on the outer end of the oligosaccharide chains. The glycans from both sources were mostly disialylated biantennary structures with a core fucose, but their content of GalNAc, SA and fucose was different. The most significant difference was in the SA content, where SA was absent in the PSA from cancer cells unlike in the PSA from the seminal fluid, where it was present in nearly all glycans. An increase in the proportion of glycan structures containing GalNAc increased from 25 % to 65 %) in PSA from cancer cells was also detected. In addition, to distinguish between PCa and BPH it was noted that free PSA was decreased in PCa patients as compared with BPH patients and that the amount of α-(2→3)-linked SA is higher in the free PSA from a PCa patient compared with that of a BPH patient. These findings can be used in the construction of lectin biosensors, since lectins are capable of detecting sugar moieties on the surface of glycoproteins.
Prostate stem cell antigen (PSCA)
PSCA is a cell surface antigen, anchored via a glycosylphosphatidylinositol-anchor to the cell membrane. It is a glycoprotein responsible for cell signalling, but its function in cell processes or tumorigenesis has not yet been fully clarified (Raff et al., 2009 ). Not only is it expressed in the prostate, but also in the stomach, kidneys, colon or bladder. A PSCA gene's expression significantly increases in a variety of PCa, bladder or pancreas cancers and decreases in esophageal and gastric cancers. It is also thought to be a tumour suppressor gene in the gastric epithelium (Reiter et al., 1998) . Studies reported that more than 94 % of prostate tumours were positive for PSCA and that there was also a correlation between a PSCA expression and GS or a tumour stage (Raff et al., 2009 ). Unfortunately, its glycan structure has not yet been described. Because the expression on the surface of PCa cells increases with tumour progression, PSCA may be a useful molecular target in the analysis of advanced PCa (Gu et al., 2000) .
Prostate specific membrane antigen (PSMA)
PSMA, also known as glutamate carboxypeptidase II, is an enzyme with the size of 84 kDa containing glycans. PSMA is a transmembrane protein, catalysing the digestion of N-acetyl-L-aspartyl-L-glutamate to glutamate and N-acetylaspartate (Knedlík et al., 2014) . PSMA is heavily N-and O-glycosylated (glycans form approximately 25 % of the total molecular mass of the protein); there are ten N-glycosylation sites predicted in the primary sequence of human PSMA and N-glycosylation is crucial for PSMA enzymatic activity and stability (Holmes et al., 1996) . PSMA has been reported as expressed in the prostate, nervous system, small intestine and kidneys (Knedlík et al., 2014) . PSMA is up-regulated in higher grade cancers, metastatic disease and hormone-refractory prostate carcinomas, hence can be used as an effective PCa marker. The highest PSMA level of all cancer tissues was reported in androgen-resistant PCa, with expression levels correlating with an in- creased cancer grade (Bostwick et al., 1998) . Glycans of PSMA derived from in vivo sources were found to be of a complex type lacking polylactosamine structures. By contrast, cancer cells were found to express only high mannose-type structures (Holmes et al., 1996) .
Haptoglobin (Hp)
Haptoglobin is a glycoprotein produced in various tissues such as liver, kidneys, lungs, etc. It is a well-known acute-phase protein and its expression increases in response to inflammation. Its role is to bind free haemoglobin (Hb) released from erythrocytes when haemolysis and tissue damage occur, as free Hb is a source of reactive oxygen species (ROS) (Andersen et al., 2012) and PCa has been linked to an increased oxidative stress (Gupta-Elera et al., 2012). Haptoglobin exhibits a low level of glycan fucosylation in healthy donors and an increased fucosylation and branching in donors diagnosed with high GS PCa. Accordingly, Hp may be a valuable PCa biomarker in distinguishing between low-and high-risk disease, and in evaluating the prognosis of a disease progress (Fujita et al., 2014) . 
Biosensors
A biosensor is a device integrating immobilised biorecognition elements in the close proximity of an appropriate transducer for bioassays (Fig. 5) (Matsumoto & Miyahara, 2013; Nagatsuka et al., 2013; Reuel et al., 2013; Szunerits et al., 2013; Tamayo et al., 2013; Barfidokht & Gooding, 2014; Mu et al., 2014; Perumal & Hashim, 2014; Sang et al., 2014; Zeng et al., 2014) . Biosensors consist of three main parts: 1) a biorecognition element for specific interaction with an analyte, 2) a physicochemical transducer to convert the biospecific signal of a biorecognition into a measurable analytical signal and 3) data storage (Fig. 6 ). All the biosensor components needed for the construction of biosensors applicable in glycoprofiling are discussed in the following sections. Moreover, in the following section, only antibodies and lectins applicable in glycoprofiling of PCa biomarkers are described.
Antibodies
Antibodies (Abs) are proteins (immunoglobulins) produced by the immune system of an organism in response to exposure to a foreign molecule -antigen (Ag) and characterised by its specific binding to a site of that molecule (an antigenic determinant or an epitope) (http://goldbook.iupac.org). A biosensor using an antibody as a biorecognition element is known as an immunosensor. In an immunosensor, Ab detects the complementary Ag and the formation of the complex Ab-Ag transduces the signal which is measurable in a variety of ways (both labelled and label-free methods) (Gopinath et al., 2014; Kluková et al., 2014) . Monoclonal and polyclonal antibodies are recognised according to their specificity. Polyclonal antibodies are molecules which are products of different cell lines and react specifically with the same Ag, but recognising various epitopes within this Ag. By contrast, monoclonal Abs are produced by a single-cell line and have a specific affinity towards the same epitope (Rich et al., 2013) . Antibodies can be divided into five classes -A, D, E, G and M. The IgG class is widely used for the construction of biosensors as they provide greater affinity and specificity towards Ag than the other classes (Zeng et al., 2012a) . IgG is a Yshaped molecule consisting of two large heavy chains (≈ 55 kDa each) and two small light chains (≈ 25 kDa each), where both have constant and variable regions and are connected by disulphide bonds (Zeng et al., 2012a) . The variable regions determine the specificity towards the Ag and are localised at both ends of the arms of an antibody (Fab -fragment, antigen binding region). The constant region is present at the stem of an Ab molecule (Fc -fragment, crystallisable region) (Murphy et al., 2008) . However, not all proteins bind to Ab in the Fab region. For example, bacterial protein A binds to the Fc region of IgG and this ability is widely used in a biosensor design where Ab binds to the immobilised protein A, exposing its Fab regions to the analyte. In this way it is possible to influence the orientation of the antibody by avoiding random orientation thereby enhancing the biosensor's sensitivity (Briand et al., 2006) . Despite protein A having five IgG binding sites, it can only bind two molecules of IgG .
As antibodies are the products of an immune sys- tem of living biological systems, it takes a long time to produce them in a useful quantity; also their quality cannot be controlled by human intervention. A way to reduce the cost and time for their manufacture is the preparation of recombinant antibodies and their production by recombinant bacteria, yeast or other cell types (Borrebaeck & Wingren, 2011) . A genetically engineered Ab is usually a fragment of the original Ab molecule, but with its targeting specificity preserved. They consist of variable regions of both the heavy and light chains, connected via an oligopeptide linker. Their great advantage is that the linker can be modified so that it contains, for example, metal-binding amino acids (e.g. cysteine), which enables them to selfassemble on the biosensor surface at high density and in the proper orientation (Zeng et al., 2012a) . Recombinant bispecific antibodies can also be produced, possessing two binding sites for each antigen, which impart increased avidity (Byrne et al., 2013) . Genetically engineered Abs can also be connected with therapeutic molecules such as radionuclides, enzymes, toxins, etc. (Holliger & Hudson, 2005) .
Lectins
Lectins (from Latin legere = to choose) are nonimmunogenic (glyco)proteins that are able to specifically bind carbohydrate structures (http://goldbook. iupac.org). Lectins do not have enzymatic activity and, due to their ability to agglutinate erythrocytes, they used to be known as agglutinins. The first lectins were isolated from plants but lectins have also been found in animals and microorganisms (Gabius et al., 2002) . Since lectins react specifically with the glycosidic residues of other molecules (e.g. cell wall polysaccharides), they have found a broad range of applications in the characterisation of a glycome -glycoprofiling. The bond between the carbohydrate (free or part of a glycoconjugate) and lectin is reversible, based on hydrogen bonds, van der Waals and hydrophobic interactions and it does not alter the structure of the glycan or glycoconjugate (Badr et al., 2014) . As lectins are a very diverse group of proteins, there are more criteria for their classification. Lectins can be classified according to their source (plant, microbial, animal and fungal), their structure (monomeric, dimeric, etc., Fig. 7) or the presence of carbohydrate moieties in their structure (Table 3) ; however, the most important criterion is their classification according to their specificity for different glycan structures (Table 3) .
There are various approaches to analysing glycans but many of them possess significant drawbacks. Glycans can be characterised by a structural analysis of glycans released from glycoproteins or by an analysis of glycopeptides from proteolysed GPs (Novotny & Alley, 2013) . However, these methods require the chemical or enzymatic alteration of a glycoconjugate molecule, hence can cause the loss of some information about the structure or a binding site of glycan. Lectinbased methods make possible the analysis of intact glycoproteins, even intact, viable cells, thus lectinbased glycoprofiling methods can be an alternative to instrumental analysis.
Transducers
Another criterion for biosensor classification is according to the type of physicochemical transducer chosen to convert a biorecognition event into a measurable signal. Of the numerous transducing techniques applicable to biosensor construction, electrochemical techniques are especially promising due to their high sensitivity of analysis, low cost of analysis, the possibilities for miniaturisation and multiplexing Bertók et al., 2013b; Kluková et al., 2014; Paleček et al., 2014 ). An electrochemical biosensor can detect small changes in the current, voltage or interfacial electrode properties (e.g. impedance, capacitance) caused by a biorecognition event on the electrode surface (Moon et al., 2014) . In general, the output signal is generated either in a label mode or without any label. The labelling of an analyte or a biorecognition element is an additional step, which renders the experiment relatively complex and could negatively affect the biorecognition event Katrlik et al., 2010; Zeng et al., 2012b; Kluková et al., 2014; Paleček et al., 2014) . Accordingly, novel analytical methods which can operate in a label-free mode are required. Here electrochemical label-free methods are discussed, affording sensitive, simple, inexpensive and rapid analysis with promising applications in a point-of-care testing. The most sensitive and reproducible methods currently applied to label-free electrochemical assays of glycans are the field-effect transistor-based and electrochemical impedance spectroscopy-based sensing (Huang et al., 2013) approaches. Field-effect sensing offers a limit of detection down to fg mL −1 (Reuel et al., 2012; Hideshima et al., 2013; Wang & Yau, 2013; Paleček et al., 2014) and reliable FET biosensors have been reported implementing polysilicon thin film transistor (Poly-Si TFT) or complementary metal-oxidesemiconductor (CMOS)-based devices (Estrela et al., 2005; Meyburg et al., 2007) . Such devices are not discussed here, but the reader is advised to read the recent literature on the topic Luo & Davis, 2013) .
Electrochemical Impedance Spectroscopy (EIS)
EIS is a popular analytical method with many applications in corrosion monitoring, the analysis of electrode kinetics, characterisation of membranes, conducting polymers, semiconductors, surface treatment protocols, batteries and fuel cells and is an ideal candidate for biosensor applications (Katz & Willner, 2003; Xu & Davis, 2014) . Accordingly, it is widely used for the characterisation of biomaterials, functionalised electrodes and biocatalytic transformations at electrode surfaces and specifically for the transduction of biosensing events at electrodes or within field-effect transistor devices (Ates, 2011; Susloparova et al., 2013) . This method Fig. 8 . Scheme of build-up of biosensor using layer-by-layer approach, by forming SAM layer on gold, by immobilisation of lectin, by blocking the surface to resist non-specific interactions and finally application of the biosensor to detect its analyte (up). Nyquist plot used for providing interfacial characteristics (i.e. R CT in form of semicircle) of interface after every building step and finally after interaction with its analyte (down). Further details are in the text.
is used to determine the electrochemical characteristics of the systems, including double-layer capacitance, impedance, determination of the rate of charge transfer and charge transport processes; and solution resistance (Barsoukov, & Macdonald 2005) . According to Ohm's law, resistance is the ratio between voltage, U, and current, I. However, this only pertains for circuits where direct current (DC) is applied. If this is the case, there is no distinction between impedance and resistance, and resistance can be regarded as impedance with a zero phase angle. Like resistance, impedance demonstrates the ability of a circuit to resist the flow of electrical current, represented by the "real impedance" term (Z r ), but it also reflects the ability of a circuit to store electrical energy, like capacitance, reflected in the "imaginary impedance" term (Z i ) (Lvovich, 2012) . The total impedance is, therefore, the sum of imaginary and real parts (1):
Impedance is expressed with the symbol Z in ohms (Ω). By modification of Ohm's law, the impedance of the system can be calculated by applying equation (2), so the impedance is expressed in terms of a magnitude (Z 0 ) and a phase shift (Φ).
EIS is based on measuring the current response by applying a small sinusoidal perturbation to an electrochemical cell. Impedance output data at the selected frequencies are consequently transformed into complex plane Nyquist plot vectors which, by application of an equivalent circuit, can provide information on the charge transfer resistance (R CT ) of a soluble redox probe (usually [Fe(CN) 6 ] 3−/4− ) (Bertók et al., 2013a) . The Nyquist plot consists of a semicircle and a linear part (Fig. 8) . The diameter of the semicircle represents the charge transfer resistance, while the linear part represents the diffusion-limited process at lower frequencies. A biorecognition event (analyte binding) causes an increase in thickness of a molecular layer on the surface, resulting in an increased R CT of the electrode and also in a limited diffusion of the redox probe to the surface, which leads to an increase in the semicircle diameter (Fig. 8) (Chen et al., 2009) . This method provides highly sensitive and reproducible results, where the limit of detection can reach attomolar levels (Bertok et al., 2013c) .
Immobilisation techniques
One of the key steps in biosensor preparation is the successful immobilisation of a biocomponent on the surface of a transducer (Bučko et al., 2012 ). An appropriate immobilisation technique should be selected in order to preserve the biocomponent's stability, to retain its binding ability and the availability of the biorecognition element for analyte-binding. The most common immobilisation techniques are adsorption, microencapsulation, entrapment, cross-linking, affinity and covalent immobilisations. The covalent attachment of biorecognition elements on the surface is the most stable method of immobilisation but it needs to be performed correctly in order to preserve the activity of a biocomponent. One of the best methods for covalent immobilisation of biorecognition elements is via the formation of a self-assembled monolayer (SAM), which forms spontaneously on some surfaces.
Self-assembled monolayers (SAMs)
SAMs are very often combined with electrochemical detection methods. The formation of a monolayer was first described by Irving Langmuir in 1917; he observed that the fatty acid film formed at the interface between air and water was formed by a single layer of molecules (Langmuir, 1917) . In biosensor constructions, SAM is used as a single layer of molecules attached to the surface of the transducer. SAM-based immobilisation provides a stable, reproducible and uniform structure while avoiding random orientation of the functional groups (Mandler & Kraus-Ophir, 2011) . SAMs can be formed on different types of surfaces such as glass, silicon oxide or noble metals, e.g. gold, silver or platinum. Molecules that make possible the formation of SAM include fatty acids, organosilicon or organosulphur compounds, consisting of the head, chain and tail with a functional group oriented towards the solution (Love et al., 2005) . The head (e.g. thiol, silane, phosphonate) attaches the adsorbate to the substrate, the chain stabilises the adsorbate when a fully formed film has developed and the tail contains the functional groups.
While a wide range of headgroups have been used in SAM research, the dominant system detailed in the literature has been alkanethiol-based SAMs formed on gold (Davis et al., 2007; Estrela et al., 2008 Estrela et al., , 2010 Guo & Li, 2014) . The alkanethiol-gold system possesses the following features: 1) gold surfaces are relatively inert to oxidation and provide a substrate, when freshly deposited, that is free of oxides and competing adsorbates; 2) strong bond between sulphur and gold (170-190 kJ mol −1 ); 3) sulphur-gold bond is formed preferentially in the presence of other competing chemical functionalities, providing the ability to modify the end of the alkanethiol with a variety of functional groups, including -OH, -NH 2 , -CN and -COOH; and 4) alkanethiol-based monolayers on gold are readily formed from a dilute solution under ambient conditions.
The ability to use -COOH and -NH 2 functional groups makes possible the formation of an amide bond between the SAM and the protein. In order to attach the protein to the -COOH group, this needs to be activated; this is commonly carried out by using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS). The carboxyl group reacts with NHS in the presence of EDC, resulting in the formation of a semistable ester which subsequently reacts with the primary amines of the protein Hermanson, 2013; Bertók et al., 2014) .
When immobilising the protein on the SAM, this monolayer acts as a barrier to keep the proteins from direct contact with the electrode surface, which would cause their denaturation (Cancino & Machado, 2012) and also makes possible control of the density and/or orientation of biorecognition elements on the surface (Gooding et al., 2003) . One method of controlling the density of functional groups on the surface is the use of mixed SAMs, prepared by the co-adsorption of two alkanethiols -one with a long chain (e.g. mercaptoundecanoic acid -MUA) and the other a "diluting" alkanethiol with a shorter chain and a different terminal group (e.g. 6-mercaptohexanol). The controlled density of the biorecognition elements decreases the steric hindrance between the bound proteins (Briand et al., 2006) . A diluting thiol can also provide functional groups resisting non-specific interactions, which is an important issue when assaying complex samples such as blood, serum and other biological fluids. The latest research is oriented towards the use of zwitterion molecules, containing phosphorylbetaine, sulphobetaine or carboxybetaine as a terminal group with anti-fouling properties (Shen & Lin, 2013) . It has been reported that construction of the SAM by co-assembling MUA and sulphobetaine led to the reduction of non-specific binding to only 6 % of a specific binding (Bertók et al., 2013b) . Another method of minimising non-specific interactions is the use of oligoand polyethylene glycol-containing biomolecules, because of their excellent protein-resistant properties, and bovine serum albumin as a blocking agent so that the analyte only binds specifically to the immobilised ligand (Davis et al., 2007 Shen & Lin, 2013) .
Nanotechnology in biosensor design
In the last decade, nanotechnology has been extensively introduced into biomedical applications such as biological detection, drug administration, diagnostics or tissue engineering (Reuel et al., 2012 (Reuel et al., , 2013 Mu et al., 2014) . This has made possible a substantial improvement in the diagnostic/therapeutic values of these methodologies. At present, the main focus of Fig. 9 . Classification of the most commonly applied nanomaterials divided into two main categories -organic and inorganic.
nanotechnology applications is on cancer research and treatment. Nanotechnology involves the study, engineering and applications of nanomaterials, which are materials, consisting of nanoparticles (NPs), with at least one dimension smaller than 100 nm (Daniel & Astruc, 2004) . On a nanoscale, the chemical, physical and biological features of materials are different from those of bulk solid matter and are controlled by quantum effects rather than by classical physics (Barkalina et al., 2014) . Irrespective of properties such as size, structure, composition and shape, nanomaterials are universally characterised by one key feature -surface area-to-volume ratio. This ratio increases when the size decreases, thus the surface phenomena predominate over the chemistry and physics of the bulk solid matter (Chen et al., 2004) . There are two large groups of nanomaterials -organic and inorganic (see Fig. 9 ).
Most electrochemical studies employ gold NPs thanks to their simple synthesis, the ability to modify their surface by thiols and biocompatibility. Gold NPs also possess the capacity to conjugate with biomolecules without altering their activity, hence they are an excellent transducer in biosensing reactions. In general, NPs can play various roles in the construction of biosensors but the most notable advantages are (Luo et al., 2006) : 1) their immobilisation on electrode surfaces generates a conductive highsurface area interface that facilitates the sensitive electrochemical detection of molecular and biomolecular analytes with a short response time; 2) NPs act as effective labels for amplified electrochemical analysis of the respective analytes; and 3) the conductivity properties of metal NPs facilitate the design of biomaterial architectures with pre-designed and controlled electrochemical functions.
Applications of electrochemical methods to glycoprofiling of PSA
The methods currently used for PSA analysis require complex instrumentation, hence are performed in dedicated laboratories; this prolongs the time from taking a sample to initiating an appropriate treatment to several weeks. The approaches most commonly used to replace these methods include but are not limited to fluorescent labelling with streptavidin-avidin technology, surface-enhanced Raman spectroscopy, realtime immuno-PCR, surface plasmon resonance or various electrochemical methods based on detecting the changes in potential, current, capacitance, conductance or impedance as a result of a biorecognition event (Healy et al., 2007) . Electrochemical biosensors with immobilised lectins have proved to be effective in the glycoprofiling of quite complex samples such as blood/serum revealing a distinct glycoprofile in samples from people with various diseases compared to a glycoprofile from a control group (Bertók et al., 2013a (Bertók et al., , 2013b Kluková et al., 2014; Paleček et al., 2014) . Such impedimetric lectin-based biosensors, after optimisation of their preparation at nanoscale or with the application of nanomaterials, were able to detect glycoproteins down to aM (10 −18 M) level (Bertok et al., 2013b (Bertok et al., , 2013c . The selective glycoprofiling of a biomarker in complex samples has to be performed in a different way. The biomarker has to be "fished out" from a complex sample using immobilised antibodies and only then can lectin be applied to detect the composition of glycan attached to the protein biomarker (Fig. 10) .
The proposed design employs lectin instead of a secondary antibody, thereby enabling the detection of different PSA glycoforms in their native form without any labelling. As these glycoforms vary depending on the stage of PCa, a lectin-based PSA immunoassay can be a valuable detection technique in PCa diagnostics. The proposed concept makes possible the cost-effective, rapid and sensitive evaluation of the patient's condition without the need for large laboratory instrumentation, hence is a promising tool for pointof-care cancer diagnosis. An extensive review of the literature showed that this concept had not yet been described for the glycoprofiling of PCa biomarkers (Paleček et al., 2014) . Recent results from our group, however, suggest that this assay protocol is viable with the ability to glycoprofile the PSA biomarker down to 10 ng mL −1 concentration (a threshold in PCa diagnostics) (unpublished results). An initiative to glycoprofile a much lower concentration of PSA is currently under way in our laboratory. The main reasons for choosing the electrochemical detection platform have already been stated but a summary of the basic biosensor characteristics for the analysis of PSA, as shown in Table 4 , convincingly demonstrates the benefits of using electrochemistry in PSA analysis with a view towards the sensitive glycoprofiling of PSA. Moreover, the application of various nanomaterials or sandwich configurations may even further enhance the desirable properties of electrochemical immunoassays.
The summary of electrochemical immunosensor characteristics given in Table 5 shows that the limit of detection for various electrochemical detection platforms is well below 10 ng mL −1 , which is a thresh-old concentration in PCa diagnostics, hence PSA can be reliably detected in the clinically relevant concentration range. Moreover, of the different electrochemical methods applied to PSA detection to date, EIS appears to be as sensitive as other electrochemical methods, with the additional advantage of EIS being a label-free mode of operation.
Conclusions
It may be concluded that changes in the glycan moiety on the protein backbone of PCa biomarkers can actually indicate PCa or indicate the stage of the disease. Although sophisticated instrumental techniques can detect glycan changes in a reliable way, such an approach can hardly be multiplexed, hence more user-friendly approaches are currently sought. The application of lectin-based biosensors is a viable alternative since these devices can detect changes in the glycan composition on the surface of intact PCa biomarkers. Of the numerous detection schemes available for the construction of biosensors, electrochemical schemes in particular provide features for highly sensitive and robust biomarker detection. In addition, EIS provides a label-free mode of detection with a sensitivity comparable to other electrochemical techniques requiring the use of redox/enzyme labels. Finally, a sandwich configuration with an antibody immobilised on the electrode surface in a controlled way applied to the selective "fishing" of an analyte from complex samples, followed by incubation of the biosensor with lectins, is a feasible concept for the glycoprofiling of PCa biomarkers. Our unpublished results suggest that this sandwich concept can work with PSA at a clinically relevant concentration and the method has the potential to quantify the concentration of PSA in the sample and, at the same time, to make possible detection of the glycan composition of this biomarker.
